Calliditas Therapeutics Ab
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jonah Hicks
- Sector
- Technology
- Industry
- Software - Application
- Address
- 1575 Post Road Richmond Sweden
- IPO Date
- Jun 6, 2025
- CIK
- 0001795579
- Website
- zonpages.com
- Similar Companies
- Business
- Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ) is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for orphan indications, with an initial emphasis on renal and hepatic diseases. Founded in 2004 and headquartered in Stockholm, Sweden, the company offers TARPEYO (budesonide) delayed release capsules and Kinpeygo for the treatment of immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression; it also advances a pipeline including setanaxib, a NOX inhibitor candidate in Phase 2 for hereditary nephritis and evaluated in head and neck cancer trials. Operations span North America, Europe, and partnerships in Asia, with distribution through collaborators such as STADA in Europe, Viatris in Japan, and Everest Medicines in China. Recent developments include Asahi Kasei Corporation's acquisition of a 93.3% stake in August 2024, making Calliditas a wholly-owned subsidiary to expand global specialty pharmaceutical presence in renal and autoimmune diseases; full European Commission approval of Kinpeygo on July 26, 2024, following positive CHMP opinion; commercial launch of Nefecon in China by Everest Medicines on May 14, 2024; positive topline Phase 2 results for setanaxib in head and neck cancer announced in 2024; and an additional seven-year orphan drug exclusivity for TARPEYO in the United States.
Clara Technologies Corp. Announces Grant of Stock Options
Clara Technologies Corp. Cancels Stock Options
Clara Technologies Engages Defiant Digital to Accelerate User Growth for Sales Buddi App
Clara Technologies Engages Social Direct Australia to Expand Global Reach of Its AI Sales Coaching Platform
Clara Technologies Initiates Multi-Phase Marketing Strategy for Sales Buddi App
Clara Technologies Announces Free Trial for Sales Buddi in Response to Positive Initial Feedback
Clara Technologies Unaware of Any Material Change
Clara Technologies Secures 14-Month Development Agreement to Advance Quantum-Enabled Sales Buddi
Clara Technologies Announces Sales Buddi Launch on Google Play Store, Extending Global Reach of Quantum-AI Sales Platform
Clara Technologies Announces Official Sales Buddi Launch on Apple App Store, Powered by Quantum-AI Engine
Clara Technologies Corp. Announces the Resignation of Oleksandr Havrylov as a Director of the Company